文献速递造血干细胞移植与细胞治疗

供者B淋巴细胞过继转移:一项针对异基因干细胞移植后患者的1/2a期研究

Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation.
PubMed 文献 · Blood Adv · 2024-01-01

该首次人体1/2a期研究评估了异基因造血干细胞移植(allo-HSCT)后过继转移供者B细胞的可行性与安全性,并检测其对回忆疫苗接种的活性。15例患者在免疫抑制减量后接受4种剂量(0.5×10^6至4.0×10^6 B细胞/kg体重)的供者B细胞,7天后接种五价疫苗。观察到浆母细胞动员及疫苗抗原血清滴度升高,较高B细胞数量组反应更强;供者B细胞转移安全,未见EBV再激活,15例中4例发生低级别GVHD。

要点

  • allo-HSCT后过继转移供者B细胞可行且安全,15例中4例出现低级别GVHD。
  • 输注后7天接种五价疫苗,观察到浆母细胞动员及疫苗抗原血清滴度升高。
  • 下一代测序显示疫苗应答浆母细胞来源于供者记忆B细胞克隆。

核心结论

  • 该首次人体1/2a期研究显示,过继转移供者B细胞在allo-HSCT后可行且安全,并能增强对回忆疫苗的体液免疫应答。
  • 作者认为该先导试验可能为探索过继转移记忆B细胞以减少allo-HSCT后感染频率的进一步研究铺路。

研究设计与样本

  • 首次人体1/2a期研究,旨在评估过继转移供者B细胞的可行性、安全性及其对回忆疫苗接种的活性。
  • 采用两步磁性细胞分选从供者单采产品制备符合良好生产规范(GMP)的B细胞产品。
  • 纳入15例已接受allo-HSCT的患者,在免疫抑制减量后治疗(中位第+148天;范围130-160天)。
  • 患者接受4种不同剂量的B细胞(0.5×10^6至4.0×10^6 B细胞/kg体重)。
  • B细胞转移后7天接种五价疫苗以检测输注的供者记忆B细胞体内活性。

主要发现

  • 观察到浆母细胞动员及针对疫苗抗原的血清滴度升高,接受较高B细胞数量的患者反应更强。
  • 通过下一代测序分析免疫球蛋白VH序列,显示对疫苗接种应答的浆母细胞起源于供者记忆B细胞克隆。
  • 供者B细胞转移安全,未观察到EBV再激活,15例中仅4例发生低级别GVHD。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is slow and patients carry a high and prolonged risk of opportunistic infections. We hypothesized that the adoptive transfer of donor B cells can foster after HSCT immuno-reconstitution. Here, we report, to our knowledge, the results of a first-in-human phase 1/2a study aimed to evaluate the feasibility and safety of adoptively transferred donor B cells and to test their activity upon recall vaccination. Good manufactoring practice (GMP) B-cell products were generated from donor apheresis products using 2-step magnetic cell separation. Fifteen patients who had undergone allo-HSCT were enrolled and treated after taper of immunosuppression (median, day +148; range, 130-160). Patients received 4 different doses of B cells (0.5 × 106 to 4.0 × 106 B cells per kg body weight). To test the activity of infused donor memory B cells in vivo, patients were vaccinated with a pentavalent vaccine 7 days after B-cell transfer. We observed the mobilization of plasmablasts and an increase in serum titers against vaccine antigens, with a stronger response in patients receiving higher B-cell numbers. Analysis of immunoglobulin VH-sequences by next-generation sequencing revealed that plasmablasts responding to vaccination originated from memory B-cell clones from the donor. Donor B-cell transfer was safe, as no Epstein-Barr virus (EBV) reactivation was observed, and only low-grade graft-versus-host disease (GVHD) occurred in 4 out of 15 patients. This pilot trial may pave the way for further studies exploring the adoptive transfer of memory B cells to reduce the frequency of infections after allo-HSCT. This trial was registered at ClinicalTrial.gov as #NCT02007811.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Winkler J, Tittlbach H, Schneider A, et al. Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation. Blood Adv. 2024. PMID: 38467031. doi:10.1182/bloodadvances.2023012305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。